Successful Scale Up of a High Yielding Viral Vector Suspension Platform to 500 L - Seguridad Mania.com - España y América Latina

As gene therapies move toward commercialization, the journey to manufacture a high-quality product while achieving economies of scale and reducing facility footprint, can be challenging. Developing and optimizing your process development early on is critical for your company’s long-term success. In this webinar, we will present our scalable integrated platforms for viral vector production in both adherent and suspension cell cultures. Key factors to consider in choosing the right technology for scaling up will be discussed in terms of factors such as cost, time, and risk. You will hear from Andelyn’s process development team and Pall’s Accelerator℠ process development experts on their strategy, proven methods, and bioprocess solutions, and on how they scaled up an Adeno-Associated Virus (AAV) manufacturing process using FectoVIR®-AAV transfection reagent to up to 500 L. Attendees will learn how to: Achieve versatility with a scalable, single-use end-to-end platform Optimize small-scale expression systems into a scalable process Achieve goals faster and better with Pall process development team